1. Home
  2. Companies
  3. IIQ
  4. Material Events

Inoviq (ASX:IIQ) — Material Events

ASX:IIQ · 16 articles in the last 12 months · 100% assessed

Click a band to jump to that tier

Significant 14 articles Notable 2 articles Not Assessed 0 articles
Major ≥90 Significant 75–89 Notable 50–74 Routine <50 Not assessed
Significant Score 75–89
14
INOVIQ Advances Cancer Diagnostics with $10.2M Raise Amid Rising LossesMedium
INOVIQ reports $3.96M half-year loss, raises A$10.2M to advance cancer diagnostics and therapeutics
18 Feb 2026 ·Appendix 4D Half-Year Financial Report ·85
INOVIQ Secures Exclusive Global Licence to Advance Early Ovarian Cancer TestMedium
INOVIQ secures exclusive global licence for ovarian cancer biomarker IP to advance EXO-OC™ test commercialization
26 Sept 2025 ·Licence Agreement Announcement ·85
INOVIQ Advances Ovarian Cancer Test Amid $6.9M FY25 Loss and $6.5M Cash ReserveMedium
INOVIQ reports FY25 loss of $6.9M, advances ovarian cancer test and CAR-exosome therapy, $6.5M cash
22 Aug 2025 ·Preliminary Final Report (Appendix 4E) and Annual Report ·85
INOVIQ Validates Breakthrough Ovarian Cancer Test, Advances CAR-Exosome TherapyMedium
INOVIQ advances exosome cancer diagnostics and therapeutics with promising EXO-OC validation and CAR-exosome preclinical data
14 July 2025 ·Investor Briefing ·85
INOVIQ Secures $10.2m to Advance Ovarian Cancer Test and CAR-Exosome TherapyHigh
INOVIQ raises A$10.2m, advances ovarian cancer test and CAR-exosome therapy with new leadership appointments
29 Jan 2026 ·Quarterly Business Update and Appendix 4C ·85
INOVIQ’s EXO-OC Test Hits 100% Early Detection Sensitivity in Ovarian CancerMedium
INOVIQ achieves breakthrough ovarian cancer test results and advances CAR-exosome cancer therapy
31 July 2025 ·Quarterly Business Update and Appendix 4C ·85
INOVIQ Secures $11.5M to Fast-Track Ovarian Cancer Test and TherapeuticsHigh
INOVIQ raises $11.5M to advance ovarian cancer test and therapeutics with Tian An Medicare as cornerstone investor
13 Oct 2025 ·Capital Raising ·85
INOVIQ Secures $9.5M to Accelerate Ovarian Cancer Test and CAR-Exosome TherapiesHigh
INOVIQ secures $9.5M funding, advances ovarian cancer test and CAR-exosome therapies with strong preclinical data
29 Oct 2025 ·Quarterly Business Update and Appendix 4C ·85
INOVIQ Advances Ovarian Cancer Test and CAR-Exosome Therapeutics with Solid Cash BackingMedium
INOVIQ advances ovarian cancer test clinical study and CAR-exosome therapeutics with strong cash position
28 Apr 2026 ·Quarterly Activities Report and Appendix 4C ·85
INOVIQ Raises A$11.5m to Accelerate Cancer Diagnostics and TherapeuticsHigh
INOVIQ launches A$11.5m capital raise to advance exosome cancer diagnostics and therapeutics pipeline
13 Oct 2025 ·Capital Raising ·85
INOVIQ’s CAR-NK-Exosomes Slash Tumors by 61.5% in Breast Cancer ModelMedium
INOVIQ’s CAR-NK-Exosome Therapy Shows Promising Breast Cancer Results and Files New Patent
22 Dec 2025 ·ASX Announcement ·85
INOVIQ’s CAR-NK-Exosomes Eradicate 90% of Aggressive Breast Cancer Cells In VitroMedium
INOVIQ’s CAR-NK-exosomes show rapid, potent tumor-killing in TNBC cells in vitro
22 Sept 2025 ·ASX Announcement ·80
INOVIQ’s CAR-Exosomes Achieve Up to 90% Tumour Kill in Ovarian Cancer CellsMedium
INOVIQ demonstrates strong in vitro tumour killing in ovarian cancer with CAR-exosomes
25 June 2026 ·Preclinical Data Announcement ·75
INOVIQ Secures $9.5M Placement, Launches $2M Share Purchase PlanMedium
INOVIQ completes $9.5M placement and launches $2M Share Purchase Plan
17 Oct 2025 ·Capital Raising ·75
Not Assessed Low Score, or missing data
0

No articles in this tier for the last 12 months.